NCT05181839 - A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions

X-Linked Hypophosphatemia

Interventions

DRUG

Burosumab

To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.

Trial Locations (14)

10117

Charité - Universitätsmedizin Berlin, Berlin

18014

Hospital Universitario Virgen a de las Nieves, Granada

30202

Hospital General Universitario Santa Lucía, Cartagena

Unknown

Centre Hospitalier Universitair de Lille, Lille

Hospices Civils De Lyon, Lyon

APHP Paris - Assistance Publique Hopitaux de Paris, Paris

University Medical Center Groningen - Beatrix Children's Hospital, Groningen

Birmingham Women's and Children's Hospital, Birmingham

Bristol Royal, Bristol

Alder Hey Children's Hospital, Liverpool

Great Ormond Street Hospital, London

08907

Hospital Saint Joan de Deu, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

M13 9WL

Royal Manchester Childrens Hospital, Manchester